News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ablexis Appoints Sean Stevens, Ph.D., as Vice President, Research


11/18/2010 12:22:09 PM

SAN FRANCISCO--(BUSINESS WIRE)--Ablexis, LLC, a biotechnology company dedicated to developing the AlivaMab Mouse, an innovative next-generation platform for antibody drug discovery, announced today the appointment of Sean Stevens, Ph.D., as vice president, research. Reporting to Larry L. Green, Ph.D., chief executive officer of Ablexis, Dr. Stevens will lead the development and assist in the ongoing commercialization of the AlivaMab Mouse platform.

Read at BioSpace.com

comments powered by Disqus
Ablexis
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES